Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Sargramostim + STEMVAC |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
STEMVAC | CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine | STEMVAC is a cancer vaccine that encodes multiple class II epitopes that result in a Th1 response upon expression, potentially leading to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10, NCI Drug Dictionary). | ||
Sargramostim | Leukine | GM-CSF|Prokine |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05242965 | Phase II | Sargramostim Sargramostim + STEMVAC | A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05455658 | Phase II | Sargramostim + STEMVAC | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | Recruiting | USA | 0 |